1,116 results on '"Herrlinger, Ulrich"'
Search Results
2. Transient MRI changes and neurological deterioration in glioblastoma upon SARS-CoV-2 infection
3. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial
4. PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma
5. Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma
6. Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment
7. Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes
8. The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
9. A H3K27M-targeted vaccine in adults with diffuse midline glioma
10. Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
11. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis
12. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
13. Incurring detriments of unplanned readmission to the intensive care unit following surgery for brain metastasis
14. Unplanned intensive care unit readmission after surgical treatment in patients with newly diagnosed glioblastoma — forfeiture of surgically achieved advantages?
15. Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations
16. Survival in patients with surgically treated brain metastases: does infratentorial location matter?
17. Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis
18. Multicentric Assessment of Safety and Efficacy of Combinatorial Adjuvant Brain Metastasis Treatment by Intraoperative Radiation Therapy and Immunotherapy
19. Methylation class oligosarcoma may encompass IDH-wildtype gliomas
20. Survival after resection of brain metastasis: impact of synchronous versus metachronous metastatic disease
21. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
22. Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
23. Disconnecting multicellular networks in brain tumours
24. Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
25. Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma
26. Perioperative red blood cell transfusion is associated with poor functional outcome and overall survival in patients with newly diagnosed glioblastoma
27. Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
28. Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedom
29. Elevated baseline C-reactive protein levels predict poor progression-free survival in sporadic vestibular schwannoma
30. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile
31. The Alcatraz‐Strategy: a roadmap to break the connectivity barrier in malignant brain tumours
32. Red blood cell distribution width to platelet ratio substantiates preoperative survival prediction in patients with newly-diagnosed glioblastoma
33. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
34. ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM
35. Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey
36. Impact of initial midline shift in glioblastoma on survival
37. Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection
38. Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography
39. Benchmarking palliative care practices in neurooncology: a german perspective.
40. Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment
41. FH-mutant glioma displaying the epigenetic signature of IDH-mutant astrocytomas.
42. No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany
43. Safety metric profiling in surgery for temporal glioblastoma: lobectomy as a supra-total resection regime preserves perioperative standard quality rates
44. Newly diagnosed glioblastoma in geriatric (65 +) patients: impact of patients frailty, comorbidity burden and obesity on overall survival
45. Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study
46. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma
47. Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
48. Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis
49. Patients with Leptomeningeal Carcinomatosis and Hydrocephalus-Feasibility of Combined Ventriculoperitoneal Shunt and Reservoir Insertion for Intrathecal Chemotherapy.
50. PATH-19. PROGNOSTIC FACTORS, RESPONSE TO TREATMENT, AND OUTCOME OF PATIENTS WITH ISOCITRATE DEHYDROGENASE (IDH)-MUTANT ASTROCYTOMA, CNS WHO GRADE 4
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.